Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab

被引：37

作者：

Elter, Thomas ^{[1
]}

Vehreschild, Janne J. ^{[1
]}

Gribben, John ^{[2
]}

Cornely, Oliver A. ^{[1
,3
]}

Engert, Andreas ^{[1
]}

Hallek, Michael ^{[1
]}

机构：

[1] Univ Cologne, Dept Hematol Oncol & Infect Dis, D-50823 Cologne, Germany

[2] Barts & London Queen Marys Sch Med & Dent, London, England

[3] Univ Cologne, Ctr Clin Trials, Cologne, Germany

来源：

ANNALS OF HEMATOLOGY | 2009年 / 88卷 / 02期

关键词：

Alemtuzumab; Campath; CLL; Infection; Management; STEM-CELL TRANSPLANTATION; VERSUS-HOST-DISEASE; WORKING-PARTY AGIHO; ANTI-CD52; MONOCLONAL-ANTIBODY; LIPOSOMAL AMPHOTERICIN-B; T-CELLS; BONE-MARROW; PHASE-II; NEUTROPENIC PATIENTS; RESIDUAL DISEASE;

D O I：

10.1007/s00277-008-0566-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Infection is a significant cause of morbidity and death in patients with chronic lymphocytic leukemia (CLL). Increased infectious events may arise from the multiple courses of immunosuppressive therapy and progressive deterioration of a patient's immune system over the course of disease. The humanized, anti-CD52 monoclonal antibody alemtuzumab (Campath or Campath-1H) has shown notable activity for both untreated and fludarabine-refractory CLL. The antibody not only targets malignant cells but also affects normal, healthy immune cells. The cumulative effects of the malignancy and successive courses of treatments adversely impinge on a patient's defense response to certain bacterial, fungal, and viral infections. In this review article, we provide an overview of common infectious events associated with alemtuzumab therapy in CLL. We also discuss recommendations for effectively monitoring and managing infections in CLL patients.

引用

页码：121 / 132

页数：12

共 64 条

[1] A European organization for Research and Treatment of Cancer - International Antimicrobial Therapy Group study of secondary infections in febrile, neutropenic patients with cancer
Akova, M
Paesmans, M
Calandra, T
Viscoli, C
[J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (02) : 239 - 245
[2] Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
Beyer, M
Kochanek, M
Darabi, K
Popov, A
Jensen, M
Endl, E
Knolle, PA
Thomas, RK
von Bergwelt-Baildon, M
Bebey, S
Hallek, M
Schultze, JL
[J]. BLOOD, 2005, 106 (06) : 2018 - 2025
[3] T-CELLS AND CD45R EXPRESSION IN B-CHRONIC LYMPHOCYTIC-LEUKEMIA
BRIGGS, PG
KRAFT, N
ATKINS, RC
[J]. LEUKEMIA RESEARCH, 1990, 14 (02) : 155 - 159
[4] Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia
Caillot, D
Couaillier, JF
Bernard, A
Casasnovas, O
Denning, DW
Mannone, L
Lopez, J
Couillault, G
Piard, F
Vagner, O
Guy, H
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 253 - 259
[5] T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival
Chakrabarti, S
MacDonald, D
Hale, G
Holder, K
Turner, V
Czarnecka, H
Thompson, J
Fegan, C
Waldmann, H
Milligan, DW
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (01) : 109 - 118
[6] Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
Chakraverty, R
Peggs, K
Chopra, R
Milligan, DW
Kottaridis, PD
Verfuerth, S
Geary, J
Thuraisundaram, D
Branson, K
Chakrabarti, S
Mahendra, P
Craddock, C
Parker, A
Hunter, A
Hale, G
Waldmann, H
Williams, CD
Yong, K
Linch, DC
Goldstone, AH
Mackinnon, S
[J]. BLOOD, 2002, 99 (03) : 1071 - 1078
[7] Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors -: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Cornely, OA
Böhme, A
Buchheidt, D
Glasmacher, A
Kahl, C
Karthaus, M
Kern, W
Krüger, W
Maschmeyer, G
Ritter, J
Salwender, HJ
Sandherr, M
Schiel, X
Schüttrumpf, S
Sieniawski, M
Silling, G
Ullmann, AJ
Wolf, HH
[J]. ANNALS OF HEMATOLOGY, 2003, 82 (Suppl 2) : S186 - S200
[8] Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
Cornely, Oliver A.
Maertens, Johan
Bresnik, Mark
Ebrahimi, Ramin
Ullmann, Andrew J.
Bouza, Emilio
Heussel, Claus Peter
Lortholary, Olivier
Rieger, Christina
Boehme, Angelika
Aoun, Mickael
Horst, Heinz-August
Thiebaut, Anne
Ruhnke, Markus
Reichert, Dietmar
Vianelli, Nicola
Krause, Stefan W.
Olavarria, Eduardo
Herbrecht, Raoul
[J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (10) : 1289 - 1297
[9] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Cornely, Oliver A.
Maertens, Johan
Winston, Drew J.
Perfect, John
Ullmann, Andrew J.
Walsh, Thomas J.
Helfgott, David
Holowiecki, Jerzy
Stockelberg, Dick
Goh, Yeow-Tee
Petrini, Mario
Hardalo, Cathy
Suresh, Ramachandran
Angulo-Gonzalez, David
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) : 348 - 359
[10] Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
Delgado, J
Thomson, K
Russell, N
Ewing, J
Stewart, W
Cook, G
Devereux, S
Lovell, R
Chopra, R
Marks, DI
Mackinnon, S
Milligan, DW
[J]. BLOOD, 2006, 107 (04) : 1724 - 1730

← 1 2 3 4 5 6 7 →